Evermay Wealth Management LLC increased its stake in shares of Celgene Co. (NASDAQ:CELG) by 134.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,423 shares of the biopharmaceutical company’s stock after buying an additional 2,535 shares during the quarter. Evermay Wealth Management LLC’s holdings in Celgene were worth $462,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of CELG. Arcadia Investment Management Corp MI boosted its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Robecosam AG acquired a new position in Celgene during the 3rd quarter worth $114,000. Capital Bank & Trust Co boosted its position in Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares during the period. Guidant Wealth Advisors acquired a new position in Celgene during the 3rd quarter worth $119,000. Finally, Balentine LLC boosted its position in Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 481 shares during the period. Hedge funds and other institutional investors own 78.60% of the company’s stock.
A number of research analysts have issued reports on the company. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target for the company in a research report on Thursday, January 25th. Mizuho set a $128.00 price target on Celgene and gave the stock a “buy” rating in a research report on Tuesday, December 26th. BTIG Research reiterated a “hold” rating on shares of Celgene in a research report on Tuesday, January 23rd. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, Citigroup reiterated a “hold” rating on shares of Celgene in a research report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Celgene has a consensus rating of “Buy” and a consensus target price of $128.22.
In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were purchased at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the transaction, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,120 shares of company stock valued at $3,879,509. 0.95% of the stock is currently owned by company insiders.
Shares of Celgene Co. (NASDAQ:CELG) opened at $88.53 on Tuesday. Celgene Co. has a fifty-two week low of $86.55 and a fifty-two week high of $147.17. The company has a market capitalization of $67,402.45, a price-to-earnings ratio of 24.73, a PEG ratio of 0.63 and a beta of 1.58. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same period in the prior year, the business posted $1.61 earnings per share. Celgene’s revenue was up 16.9% compared to the same quarter last year. sell-side analysts anticipate that Celgene Co. will post 7.66 EPS for the current year.
Celgene declared that its board has authorized a stock repurchase plan on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.